



COMPANY OVERVIEW

Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. On May 26, 2016, the U.S. Food and Drug Administration approved Probuphine for the long-term maintenance treatment of opioid dependence in stable patients receiving a low to moderate daily dose of oral buprenorphine therapy. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure.

RECENT NEWS

[Titan Pharmaceuticals Announces Reverse Stock Split](#)

Nov 30 2020, 12:50 PM EST

[Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results](#)

Nov 16 2020, 8:45 AM EST

STOCK OVERVIEW

Symbol	TTNP
Exchange	Nasdaq
Market Cap	22.96m
Last Price	\$3.50
52-Week Range	\$2.82 - \$16.35

12/04/2020 04:00 PM EST

INVESTOR RELATIONS

Stephen Kilmer
T: 650-989-2215
skilmer@titanpharm.com

MANAGEMENT TEAM

Marc Rubin, MD
Executive Chairman

Kate DeVarney, Ph.D.
President and Chief Operating Officer

TITAN PHARMACEUTICALS, INC.

400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080-1958
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.